1.09
前日終値:
$1.08
開ける:
$1.1
24時間の取引高:
307.55K
Relative Volume:
0.57
時価総額:
$67.49M
収益:
$248.00K
当期純損益:
$-113.22M
株価収益率:
-0.5919
EPS:
-1.8416
ネットキャッシュフロー:
$-98.81M
1週間 パフォーマンス:
-5.22%
1か月 パフォーマンス:
-3.54%
6か月 パフォーマンス:
-16.15%
1年 パフォーマンス:
-31.45%
Pliant Therapeutics Inc Stock (PLRX) Company Profile
名前
Pliant Therapeutics Inc
セクター
電話
650-481-6770
住所
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
PLRX
Pliant Therapeutics Inc
|
1.09 | 67.49M | 248.00K | -113.22M | -98.81M | -1.8416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-03-04 | 再開されました | Cantor Fitzgerald | Neutral |
| 2025-03-04 | ダウングレード | Needham | Buy → Hold |
| 2025-03-03 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | ダウングレード | Stifel | Buy → Hold |
| 2025-02-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-02-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-02-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-02-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-05-18 | 開始されました | Canaccord Genuity | Buy |
| 2023-04-13 | 開始されました | Robert W. Baird | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-07 | 開始されました | JP Morgan | Overweight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Outperform |
| 2022-05-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-03 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-20 | 開始されました | BTIG Research | Buy |
| 2021-04-05 | 開始されました | Citigroup | Buy |
| 2020-06-29 | 開始されました | Citigroup | Buy |
| 2020-06-29 | 開始されました | Cowen | Outperform |
| 2020-06-29 | 開始されました | Needham | Buy |
| 2020-06-29 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Pliant Therapeutics Inc (PLRX) 最新ニュース
Pliant Therapeutics Inc (PLRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PLRX|Pliant Therapeutics Inc|Price:1.090|Chg%:+0.010 - TradingKey
Pliant Therapeutics Inc (PLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pliant Therapeutics Inc (PLRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pliant Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information and NASDAQ Listing - Minichart
Form 4 Pliant Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Pliant Therapeutics adds independent directors to strengthen R&D - TipRanks
Pliant Therapeutics (PLRX) director Robert Iannone submits initial Form 3 - Stock Titan
Pliant Therapeutics (PLRX) director files initial insider ownership statement - Stock Titan
Pliant Therapeutics (PLRX) awards 60,000 stock options to director Flavia Borellini - Stock Titan
[8-K] PLIANT THERAPEUTICS, INC. Reports Material Event - Stock Titan
Pliant Therapeutics adds two directors with oncology expertise - Investing.com UK
Pliant Therapeutics appoints Flavia Borellini to board, strengthening executive leadership - Traders Union
Pliant Therapeutics adds two directors with oncology expertise By Investing.com - Investing.com Nigeria
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors - The Manila Times
Price to sales forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Price to earnings forward of Pliant Therapeutics, Inc. – FWB:9PT - TradingView
Price to book forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Enterprise value to revenue forward of Pliant Therapeutics, Inc. – FWB:9PT - TradingView
Enterprise value to revenue forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Price to earnings forward of Pliant Therapeutics, Inc. – TRADEGATE:9PT - TradingView
Pliant Therapeutics (PLRX) Stock Edges Lower, Holds Closely Above Key SupportAccumulation Line - dars.gov.et
Pliant Therapeutics (PLRX) Holds Steady at $1.17 as Traders Eye Key Support and Resistance LevelsVolume Dry Up - dars.gov.et
Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – GETTEX:9PT - TradingView
Pliant Therapeutics Inc. (PLRX) Q1 2026 Earnings: Narrower Loss Sends Stock HigherTech Earnings Analysis - dars.gov.et
Pliant Therapeutics (PLRX) Edges Higher Amid Consolidation Near SupportPre-Earnings Momentum - dars.gov.et
Pliant Therapeutics Inc. (PLRX) Q1 2026 Earnings: EPS Beat Highlights Cost DisciplineSegment Revenue Breakdown - dars.gov.et
PLRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pliant Therapeutics (PLRX) Inches Higher Amid Ongoing Volatility: Key Levels to WatchMerger Arbitrage - dars.gov.et
Pliant Therapeutics Inc (PLRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
9PT Forecast — Price Target — Prediction for 2027 - TradingView
Pliant Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLRX) - TradingView
PLRX Forecast — Price Target — Prediction for 2027 - TradingView
Pliant Therapeutics (PLRX) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesManagement Guidance Update - DonanımHaber
Pliant Therapeutics Inc (PLRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pliant Therapeutics Inc (PLRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pliant Therapeutics Inc (PLRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pliant Therapeutics Inc (PLRX) Institutional Confidence - TradingKey
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pliant Therapeutics (PLRX) director receives 70,000 stock options at $1.14 - Stock Titan
Pliant Therapeutics (PLRX) director granted 70,000 options at $1.14 strike - Stock Titan
Pliant Therapeutics (PLRX) director receives 70,000-share stock option grant - Stock Titan
Pliant (NASDAQ: PLRX) director awarded 70,000 stock options at $1.14 - Stock Titan
PLIANT THERAPEUTICS (PLRX) director granted 70,000 stock options at $1.14 - Stock Titan
Director Darren Cline receives 70,000 PLRX stock options at $1.14 strike price - Stock Titan
Pliant Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Huh Hoyoung - Moomoo
Pliant Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Pliant Therapeutics (NASDAQ: PLRX) reports 2026 director, pay and auditor votes - Stock Titan
PLIANT THERAPEUTICS INC (PLRX) Stock Chart - ChartMill
Pliant Therapeutics Inc (PLRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):